Combination Drug Approved for High Blood Pressure

Tribenzor sanctioned for those who don't respond to other drugs

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

MONDAY, July 26, 2010 (HealthDay News) -- Tribenzor, a three-in-one drug to treat high blood pressure, has been approved by the U.S. Food and Drug Administration.

Tribenzor combines amlodipine, marketed by Pfizer as Norvasc, olmesartan medoxomil, marketed by Daiichi Sankyo as Benicar, and a third drug, hydrochlorothiazide. The combination medication was approved for people whose high blood pressure isn't well controlled on other combinations of anti-hypertension drugs.

Daiichi Sankyo, based in Japan with U.S. headquarters in Parsippany, N.J., produces the newly approved drug.

In a news release, the company said adverse reactions to once-daily Tribenzor could include dizziness, swelling, headache, fatigue, muscle spasms, nausea, diarrhea or infections of the respiratory or urinary tracts.

More information

To learn more about high blood pressure, visit the U.S. National Heart Lung and Blood Institute.

--

Last Updated: